Evaluation of the Clinical Impact of Adjunctive L-carnitine Therapy in Critically Ill Hepatic Patients Admitted to Intensive Care Unit

ConditionHepatic
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeni-Suef University

About this trial

This study aims to evaluate the possible efficacy of l-carnitine in critically ill hepatic patients admitted to intensive care unit.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age more than 18 years old

Acute-on-chronic liver failure (ACLF)

Hepatic encephalopathy

spontaneous bacterial peritonitis (SBP)

Disqualifiers

Age of less than 18 years old

Pregnancy or Lactation

patients have seizure

patient on warfarin

Trial design

Design model

Parallel

Treatments tested in this trial

  • L Carnitine

    Drug

    L-Carnitine, a natural substance present in the body, is essential for energy metabolism in mammals. l-carnitine presents as a drug.

  • Standard medical treatment

    Drug

    Standard medical treatment for hepatic patient admitted to icu

Treatment groups

58 Participants
are divided into 2 treatment groups
Group A: control groupActive comparator 1 intervention
Group B: test groupActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

laboratory value: serum creatinine(SCr)

Time frame
At ICU admission and at ICU discharge, an average of 7 days
2

laboratory value: international normalized ratio

Time frame
At ICU admission and at ICU discharge, an average of 7 days
3

laboratory value: Blood urea nitrogen(BUN)

Time frame
At ICU admission and at ICU discharge, an average of 7 days
4

laboratory value: Albumin

Time frame
At ICU admission and at ICU discharge, an average of 7 days

Secondary outcomes

Other outcomes

1

• hospitalization stay in ICU

Time frame
At ICU admission and at ICU discharge, an average of 7 days

Sponsors and contacts

Click on the lead sponsor to view all of their trials.